Trial
NCT05660265
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Hematologic Diseases
Intervention
GSK4172239D
Why stopped
Sponsor decision to terminate the study due to strategic business consideration and not related to safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-22